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Introduction: Traumatic brain injury (TBI), a significant cause of death and disability, causes, as in any injury, an
acute, innate immune response. A key component in the transition between innate and adaptive immunity is the
processing and presentation of antigen by professional antigen presenting cells (APCs). Whether an adaptive
immune response to brain injury is beneficial or detrimental is not known. Current efforts to understand the
contribution of the immune system after TBI have focused on neuroinflammation and brain-infiltrating immune
cells. Here, we characterize and target TBI-induced expansion of peripheral immune cells that may act as potential
APCs. Because MHC Class II-associated invariant peptide (CLIP) is important for antigen processing and presentation,
we engineered a competitive antagonist (CAP) for CLIP, and tested the hypothesis that peptide competition could
reverse or prevent neurodegeneration after TBI.
Results: We show that after fluid percussion injury (FPI), peripheral splenic lymphocytes, including CD4+ and CD8+ T
cells, regulatory T cells (Tregs), and γδ T cells, are increased in number within 24 hours after FPI. These increases were
reversed by CAP treatment and this antagonism of CLIP also reduced neuroinflammation and neurodegeneration after
TBI. Using a mouse deficient for the precursor of CLIP, CD74, we observed decreased peripheral lymphocyte activation,
decreased neurodegeneration, and a significantly smaller lesion size following TBI.
Conclusion: Taken together, the data support the hypothesis that neurodegeneration following TBI is dependent upon
antigen processing and presentation that requires CD74.
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Traumatic brain injury (TBI) is a leading cause of death
and disability in the United States and throughout the
world [1-3]. To date, there are no effective treatments to
prevent or reverse damage after TBI. Due to the direct
impact on the brain, efforts at diagnosis and treatment
of TBI have been primarily focused on the central ner-
vous system (CNS). However, it is now well established
that peripheral immune mechanisms are involved in the
pathology associated with TBI [4-7]. The paradigm that* Correspondence: newellrogers@tamhsc.edu
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unless otherwise stated.has been widely accepted is that the blood brain barrier
(BBB) serves as the primary obstacle to the recruitment
of leukocytes that could otherwise cause harm to the
brain [7,8]. However, after TBI, there is BBB breakdown
and one result is the passage of peripheral immune cells
into the CNS [7].
In general, an immune response will begin with an in-
nate and immediate response to injury that includes ac-
tivation and migration of neutrophils, dendritic cells,
macrophages (including microglial cells in the CNS), as
well as other less defined cellular and molecular compo-
nents [9-11]. The innate immune response is typically
followed by the antigen-specific, adaptive immune re-
sponse. The transition from an innate to an adaptivetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cessing and presentation, by professional antigen pre-
senting cells (APCs), to antigen-specific T lymphocytes
[12,13]. How, or if, damage to the brain, often de-
scribed as an “immune-privileged” site [14], elicits an
innate, and the transition to, an adaptive immune re-
sponse from peripheral immune mediators to the CNS,
is not known. Evidence for the involvement of antigen
processing and presentation in the CNS is provided by
the study of Slavin et al. [15]. This study demonstrated
that mice lacking the machinery for processing and
presentation of full-length myelin basic protein did not
develop experimental autoimmune encephalomyelitis
(EAE), a mouse model for Multiple Sclerosis (MS).
However, when these same mice were exposed to pep-
tides derived from full-length myelin basic protein, the
mice became susceptible to EAE. Interestingly, Ling
et al. demonstrated that TBI results in recruitment of
antigen-specific CD8+ T cells, only in the presence of
the antigen for which they are specific [16]. Further-
more, in a model of optic neuritis, the acute immune
response leads to an adaptive, specific, anti-brain re-
sponse [17-19]. Conflicting reports suggest that this ef-
fect could be either harmful or helpful to recovery
[5,6]. Regardless of their role in the outcome, these
findings provide evidence for an adaptive immune re-
sponse in the brain after TBI.
Efficient antigen processing and presentation via the
major histocompatibility complex II (MHCII) pathway
in APCs, including macrophages, microglia, dendritic
cells, B cells, and γδ T cells, facilitates the transition be-
tween innate and adaptive immunity [13,20-22]. Antigen
processing and presentation by these professional APCs
involves invariant chain (CD74). CD74 serves as a
chaperone for MHCII until CD74 is proteolytically
cleaved into Class II invariant peptides (CLIP) that fill
the antigen-binding groove of MHCII molecules [12,23].
Replacement of CLIP by antigenic peptides and T cell rec-
ognition of antigenic peptide in MHCII is the first step in
T cell activation, and the first event in a T cell-mediated
adaptive immune response [13,20,24]. This vital step of
peptide exchange between innate and adaptive immunity
has not been elucidated following TBI. Critical to this
process is the cleavage of full-length CD74 into CLIP, the
loading of CLIP into the antigenic binding groove of
MHCII, followed by the replacement of CLIP with anti-
genic peptides [23]. Therefore, we engineered and synthe-
sized a peptide that competitively antagonizes the antigen-
binding site of MHCII, to determine if antagonism of
CLIP/antigenic peptide exchange might prevent or reverse
the detrimental effects of TBI [25]. Thus, this study was
designed to determine if exchanging CLIP for antigenic
peptide is important in secondary neurodegeneration
following TBI.Materials and methods
Treatment with competitive antagonist peptide (CAP)
CAP was synthesized as previously described [25]. Briefly,
using computational design, we identified a 9mer peptide,
with 8 total amino acid flanking regions, that by, peptide
binding analysis software (MHCPred and netMHC), was
predicted to have a higher binding constant than the in-
variant peptide CLIP for the peptide-binding groove of
known MHCII alleles. CAP was synthesized by Elim Bio-
pharmaceuticals. The mice were injected intraperitoneally
(i.p.) (1 mg/kg) with CAP. CAP was initially dissolved at
5 mg/mL in dimethyl sulfoxide (DMSO), after which 5 μl
of CAP dissolved in DMSO was further diluted with 195 μl
of sterile saline and injected (I.P.). In vehicle injected mice,
an injection containing 5 μl DMSO dissolved in 195 μl of
sterile saline.
Animals
6-week-old male C57BL/6 J (N = 16) were purchased
from Jackson Labs. Invariant chain deficient (CD74Def )
mice (C57BL/6 background; N = 16) were purchased
from Jackson Labs and bred at the Scott and White
Healthcare animal facility to maintain homozygous
CD74 deficiency. Because littermates are not available
to compare with the CD74Def mice (as they are bred to
homozygosity), we have used age and sex matched
C57BL/6 mice (the background strain for the mice). All
mouse care, housing, and experimental procedures were
approved by the Baylor Scott and White Healthcare In-
stitutional Animal Care and Use Committee, reference
number 2013-021. Wild type mice were divided into
four groups for flow cytometry and multiplexing and
sacrificed at 24 hrs after TBI. These four groups were:
sham + vehicle (N = 6); sham +CAP (N= 5); FPI + vehicle
(N = 7 WT); FPI + CAP (N= 6). For the CD74Def mice,
two groups were used. These two groups were: Sham
(N = 7 CD74Def ) and FPI (N = 6 CD74Def ). In addition,
we used separate mice for histological studies and
these mice were sacrificed 3 days after TBI (N = 6 WT
sham+ vehicle, 5 FPI + CAP, and 5 CD74Def ). The three
day post-TBI time point was selected because our previ-
ous study indicated that this is when the peak of TBI-
induced neurodegeneration was observed [26].
Fluid percussion injury (FPI)
FPI was induced as previously described [26]. Briefly, mice
were anesthetized with isoflurane, prepped, cleaned, and
shaved, then put into a stereotactic instrument (Stoelting,
Inc.). A 2 mm craniotomy was made over the left parietal
cortex making sure to keep the dura intact. The female
end of a luer lock syringe was cemented over the craniot-
omy and attached to the fluid percussion apparatus. A
12–16 ms FPI was delivered at a pressure of ~1.4-
1.6 atm. Sham mice received identical treatment except
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sham, suture was used to close the scalp over the wound
and mice were returned to their home cage resting on a
heating pad. Mice were monitored to ensure that they re-
sumed walking, feeding, drinking and grooming behavior.Flow cytometry
Mice were sacrificed and spleens were removed. The tis-
sues were dissociated, single cell suspensions prepared, and
red blood cells were lysed using GEY’S buffer [27]. The dis-
sociated splenocytes were treated with FC Block (BD Bio-
science) and then stained with the following antibodies;
CD3, CD4, CD8, CD25, MHCII (clone M5/114.15.1), B220,
γδ-TCR (BD Bioscience), and CLIP (15G4, Santa Cruz
Biotechnology). For regulatory T cell (Treg) staining we
used the eBioscience mouse regulatory T cell staining Kit
according to the manufacturer’s directions. Live cells were
assessed using the Life Technologies LIVE/DEAD® Fixable
Aqua Dead Cell Stain Kit according to the manufacturer’s
directions. Splenocytes were analyzed using a BD FACS
Canto II flow cytometer and data were analyzed using
FlowJo software (TreeStar Inc.). See Additional file 1:
Figure S1 for gating strategy.FluoroJade C method
Fluorojade C staining took place as previously described
[26]. Briefly, every 6th 50 um section was analyzed
within the margins of the lesion. This corresponded to
5–7 sections per mouse. Sections were mounted onto
gelatin-coated slides and FluoroJade C histology was per-
formed as previously described [26]. The slides were
allowed to air dry, after which cover slips were applied
using Vectashield with DAPI (Vector Labs). Prior to
analysis, slides were coded to ensure that the reviewer
was blind to the condition of the mice. Sections were
then visualized using an Olympus IX81 (Olympus Inc.,
Tokyo, Japan) inverted microscope equipped to visualize
FITC. We used the following Olympus UplanS objec-
tives to capture the images: 10× NA0.40 ∞/0.17 FN26.5;
20× nA0.75 ∞/0.17 FN26.5; 40× NA0.75 ∞/0.17 FN26.5.
Images were captured using the FV1000 and the Fluoview
software (V. 1.7.1.0). Images were saved as 24 Bit Tiff files
and brightness and contrast were adjusted using Adobe
Photoshop (V. 12.0). For quantitative analysis of Fluor-
ojade C labeling, the peri-lesion area was traced and
400 μm2 grids were randomly placed throughout the
traced area. All cells which fell within the grid, or con-
tacted the left and upper borders of the grid were in-
cluded in the counts, whereas those that touched the
right or lower border were excluded. The peri-lesion
area consisted of +/− 1 mm anterior/posterior (AP)
from the injury focus (AP +1.5 mm; medio-lateral:
1.2 mm).Measurement of lesion size
Superficial lesion size was measured using a digital cali-
per (Mitutoyo 150 mm, .01 mm accuracy) as previously
described [28,29]. In order to confirm superficial lesion
measurements made with the digital caliper, we assessed
the margins of the lesion in the anterior posterior plane,
and calculated the expanse of the lesion using a mouse
atlas [30]. Initially, every 6th 50 μm Nissl stained section
was used for determination. However, in some cases, it
was necessary to examine serial sections in which Fluor-
ojade C (or other stains not reported in this manuscript)
was stained, in order to confirm that we had accurately
accounted for the most anterior and posterior margins
of the lesion. It should be noted that considering the
margin of error of the digital caliper (100 μm) and the
distance between brain slices in the mouse atlas (100–
140 μm), all measurements were within the margin of
error of these 2 sources.Cytokine analysis
Fresh, non-perfused tissue was isolated from the ipsilateral
cortex including the lesion area and flash frozen in liquid
nitrogen. Frozen tissue was homogenized following the
manufacturer’s instructions (Milliplex MAP kit, Millipore).
Protein was estimated with a Bradford assay and similar
concentrations were made such that 25 μl of homogenate
was added to 25 μl of assay buffer. Then, 25 μl of magnetic
beads coated with specific antibodies (MCYTOMAG-
70 K-PMX, Milliplex MAP Kit, Millipore) was added to
this solution and the reaction was incubated at 4°C for
24 hours. Next, the beads were washed and incubated
with 25 μl of biotinylated detection antibody at room
temperature (RT) for 2 hours. Finally, 25 μl of Streptavi-
din–Phycoerythrin conjugate compound was added and
incubated for 30 min at RT. The beads were then
washed and incubated with 150 μl of sheath fluid for
5 min at RT. The concentration of the analytes is then
determined by Bio-Plex Manager software version 5.0.
The assays were run in triplicate to confirm the results.
Analytes were normalized to total protein concentra-
tion. In cases where the cytokines in the brain tissue
of three or more mice for a group were below the de-
tection threshold, the data were not presented in the
graphs.Statistical analysis
Statistical analysis was performed using GraphPad Prism
6 (GraphPad Software Inc.). For comparisons between
splenocytes from C57BL/6 J and CD74Deff, a t-test was
used with a significance cut-off of P <0.05. For all other
analysis, repeated measures ANOVA was used with
post-hoc planned comparisons using Dunnett’s correc-
tion factor.
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Expansion of peripheral lymphocytes following Fluid
Percussion Injury (FPI)
To characterize the changes in peripheral immune cells
following TBI, splenic lymphocytes were harvested at
24 hours after FPI and analyzed using flow cytometry.
The results showed that the overall splenic cellularity
was significantly increased (P < 0.017) in FPI-treated
mice compared to sham-treated controls and this effect
was prevented by administration of competitive antag-
onist peptide (CAP) (Figure 1A). While there was a
trend toward increased B220+ B cells (Figure 1B), there
was a significant (P < 0.03) reduction in B cell numbers
following CAP treatment after FPI (Figure 1B). In
addition, there was a significant (P < 0.001) FPI-induced
increase in the total number of CD3+ T cells that was
significantly (P < 0.001) reduced by CAP treatment after
FPI (Figure 1C). Specifically, CD4+ T cells were also sig-
nificantly increased in number (P < 0.014) and their num-
bers were significantly reduced (P < 0.018) following CAPFigure 1 Selective expansion of splenic immune cell subsets in respo
C57BL/6 mice 24 hours following sham surgery or FPI. TBI significantly incr
showing a trend toward B cell expansion after FPI that does not reach sign
after FPI. (C) Analysis of T cells (CD3+) revealed a significant expansion afte
of CD3+ T cells, CD4+ T cells (CD3+CD4+), are also significantly elevated aft
(E) Identification of Tregs (CD3+CD4+CD25HiFoxP3+) also revealed a signific
populations, this population is also significantly decreased after CAP treatm
T cells (CD3+γδ-TCR+) and this increase is significantly reduced by our CAP
also revealed a significant increase after FPI that is significantly reduced wit
observed for activated CD4+ T cells (CD3+CD4+CD25+FoxP3−) in the spleens o
(N = 6); sham + CAP (N = 5); FPI + vehicle (N = 7 WT); FPI + CAP (N = 6). The sytreatment (Figure 1D). There were also significant in-
creases in Tregs (P < 0.018), as defined by CD3+, CD4+,
high CD25 and expression of the transcription factor
FoxP3 (Figure 1E), γδ T cells (P < 0.0.14); (Figure 1F) and
CD8+ T cells (P < 0.02); (Figure 1G), all of which were sig-
nificantly reduced by treatment with CAP (Figures 1E-G).
In contrast, there was no significant increase in the num-
bers of conventional activated CD4+ T cells, nor was there
a significant reduction of these cells following CAP treat-
ment (Figure 1H).
FPI-induced changes in components of antigen
presentation by peripheral lymphocytes
A hallmark of the transition between innate and adaptive
(specific) immunity is successful antigen processing and
presentation. Antigen processing requires proteolytic
cleavage of invariant chain (CD74) into peptides known as
class II invariant peptide (CLIP). CLIP functions as a
“placeholder” for antigen specific binding to the peptide-
binding groove of MHCII molecules. B cells and γδ T cellsnse to FPI. (A) The number of viable cells in the spleens (cellularity) of
eased the number of viable cells. (B) The number of B cells (B220+)
ificance. However, treatment with CAP significantly reduced B cells
r FPI that is significantly reduced following CAP treatment. (D) A subset
er FPI. This elevation is significantly reduced following CAP treatment.
ant increase in this cellular population after TBI. Similar to other T cell
ent. (F) A similar pattern of FPI-induced increase is observed for γδ
treatment. (G) Analysis of CD8+ cytotoxic T lymphocytes (CD3+CD8+)
h our CAP treatment. (H) Alternatively, no significant differences were
f C57BL/6 mice 24 hours following sham surgery or FPI. Sham+ vehicle
mbol * indicates P < 0.05.
Tobin et al. Acta Neuropathologica Communications 2014, 2:143 Page 5 of 10
http://www.actaneurocomms.org/content/2/1/143are among cells that are well characterized as professional
APCs [31,22]. Therefore, we examined the effects of FPI
on CLIP and MHCII from peripheral lymphocytes. We
observed a significant decrease in cell surface CLIP on B
cells (Figure 2A). Conversely, we observed no correspond-
ing changes in the cell surface levels of MHC II on B cells
(Figure 2B). In contrast to CLIP on B cells, we observed
no significant differences in the level of CLIP per γδ T
cells (Figure 2C), but a significant decrease in MHCII on
γδ T cells (Figure 2D). These results suggest possible FPI-
induced alterations to molecular machinery involved in
antigen processing and presentation.
To test the effect of our peptide on influencing the
transition between innate and adaptive immunity, we ex-
amined CLIP and MHCII expression on B cells and γδ T
cells in mice administered CAP 20 minutes after FPI. We
examined these two cell types because they are known to
express MHCII and present antigens. We observed no sig-
nificant differences in CLIP expression on the cell surface
of B220+ B cells (Additional file 2: Figure S2) following
CAP administration after FPI. These results suggest that
of these 2 potential APCs (B cells or γδ T cells), the data
are more consistent with B cells functioning as APCs in
response to TBI. In contrast, the data are less suggestive
of γδ T cells serving as APCs based on reduced MHCII
(Figure 2D) and therefore a higher ratio of CLIP to MHCII
on γδ T cells.
Absence of FPI-induced lymphocyte expansion in
invariant chain deficient mice
Because we observed changes in CLIP expression result-
ing from FPI, we sought to determine the significance of
CLIP involvement in immune modulation by FPI, by using
mice deficient in invariant chain, CD74. CD74, which is
required for processing and presentation of full-lengthFigure 2 Differential expression of MHCII and CLIP on B and γδ T cell
indicative of the level of cell surface expression of CLIP is significantly redu
CLIP likely reflects replacement of CLIP by other peptides. (B) Consistent w
of MHCII on the surface of B cells was observed at 24 hours after FPI. (C) In
unchanged, (D) while the level of MHCII significantly decreased at 24 hour
candidate as APCs after FPI. Sham + vehicle (N = 6); FPI + vehicle (N = 7). Thproteins [18,15], can serve as a survival factor and can
function as a growth promoting receptor. In support of
the notion that CD74 is required for lymphocyte ex-
pansion following FPI, mice lacking CD74 exhibited no
net change in spleen cellularity 24 hours following FPI
(Figure 3A). Alternatively, wild type mice exhibit a signifi-
cant expansion of lymphocytes in the spleen at 24 hrs after
FPI (Figure 1A). Furthermore, there were no changes in
numbers or activation state of any of the subsets of B or T
cells (Figure 3B and C, respectively).CLIP antagonism or invariant chain deficiency modifies
the cytokine profile in the CNS following FPI
Our previous work has identified numerous changes in
cytokines and chemokines in the CNS following an FPI
[32]. Because CAP reduced the number of activated sple-
nocytes following FPI, and activated splenocytes are a
potential source of cytokines and chemokines, we sought
to determine if CLIP antagonism using CAP modifies the
cytokine milieu in the CNS. In order to address this, we
screened for multiple cytokines, using a Multiplex cyto-
kine assay system (MCYTOMAG-70 K-PMX). The results
showed that CAP treatment significantly reduced IL15,
IL13, IL10 and monocyte chemoattractant protein (MCP1),
also known as CCL2 (Figure 4).
Because the absence of invariant chain in the CD74def
mice resulted in no splenocyte activation after FPI, we
similarly sought to examine the cytokine and chemokine
expression in the brains of these KO mice after FPI. We
observed significantly less TBI-induced expression of IFNγ,
TNFα, regulated on activation normal T cell expressed and
secreted (RANTES; AKA CCL5), macrophage inflam-
matory protein 1β (MIP1β; AKA CCL4) and IL-13, in
the CNS of CD74def mice when compared to C57BL/6s in response to FPI. (A) The mean fluorescence intensity (MFI),
ced on the surface of B cells at 24 hours after FPI. This reduction in
ith this interpretation, no corresponding significant decrease in the MFI
contrast, the MFI of CLIP on the surface of γδ T cells remained
s after FPI. Taken together, these data suggest that B cells are a likely
e symbol * indicates P < 0.05.
Figure 3 FPI-induced alterations in peripheral lymphocytes require CD74. (A) The number of viable cells in the spleens of CD74Def mice is
unchanged at 24 hours following sham surgery or FPI. (B) Similarly, the number of B Cells (B220+) and T cells (CD3+) in the spleens of CD74Def
mice are not significantly different at 24 hours after sham surgery or FPI. (C) Analysis of specific populations of T cells also revelaed no significant
differences at 24 hours after sham surgery or FPI. For these experiments we used 5 sham surgery mice and 6 FPI treated mice. The
symbol * indicates P < 0.05.
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(Figure 5).
Invariant chain deficiency or CLIP antagonism confers
neuroprotection from FPI
To determine the contribution of CD74 to FPI-induced
neurodegeneration, we examined FluoroJade C labeling
at 3 days after FPI in WT and CD74Def mice. The 3 day
time point was selected because we previously demon-
strated that this was the peak of neurodegeneration fol-
lowing FPI [26]. The results demonstrate that relative to
vehicle treatment (Figure 6A), treatment with CAP signifi-
cantly reduced the number of FluoroJade C-labeled cells
in the ipsilateral cortex (Figure 6B). Similarly, mice defi-
cient for CD74 (Figure 6C) had decreased FluoroJade C-
labeling compared to vehicle treatment (Figure 6A). In
addition, Analysis of the overall lesion size revealed that
both, CAP treated and CD74def mice had a significantly
smaller lesion size compared to WT mice (Figure 6D).
Quantitation of Fluorojade-staining in the brain following
CAP administration and in CD74def mice, demonstrated a
significant reduction in degenerating cells (Figure 6E).Figure 4 CAP decreases expression of pro-inflammatory cytokines in
the ipsilateral cortex of C57BL/6 mice following FPI. Note the significant red
subset of chemokines and cytokines is consistent with the reduction in cel
(N = 4); sham + CAP (N = 4); FPI + vehicle (N = 4); FPI + CAP (N = 4). The symDiscussion
This study is the first to demonstrate a putative role for
invariant chain CD74 in CNS damage following brain in-
jury. The data support targeting the transition between
innate and adaptive immunity in the periphery as a po-
tential therapeutic approach for TBI. Alterations to per-
ipheral immune cell populations include an increase in
cellularity in the spleen, comprised of increased B cells,
CD3+ T cells, CD4+ T cells, CD8+ T cells, Tregs and γδ
T cells. Further, we found that TBI induces a decrease in
cell surface CLIP on B220+ B cells, and a decrease in
MHCII on activated γδ T cells, suggesting that B cells
may be the dominant APC after TBI. We also determined
by using CD74Def mice, that these changes were invariant
chain dependent.
The fact that CLIP antagonism and CD74Def mice have
a reduced lesion size and decreased neurodegeneration
after TBI, supports the involvement of CLIP and/or
CD74 in mediating damage in the CNS. Both CD74 and
its products, including CLIP, are widely accepted as cen-
tral players in antigen processing and presentation, and
are central to the transition between innate and adaptivethe brain following FPI. Multiplex analysis of cytokines in tissue from
uctions in IL-13, IL-15, CCL2 (MCP1), and IL-10. The reduction of this
ls capable of producing these inflammatory cytokines. Sham + vehicle
bol * indicates P < 0.05.
Figure 5 CD74Def mice are resistant to FPI-induced increases in pro-inflammatory cytokines in the brain following TBI. Multiplex analysis
of cytokine expression in tissue from the ipsilateral cortex, comparing the cytokine response to FPI in wild type C57BL/6 mice to CD74Def mice.
The results demonstrate a significant decrease in the levels of TNFα, IFNγ, RANTES, MIP1β, and IL-13 in tissue from the ipsilateral cortex of CD74Def
mice compared to C57BL/6 mice, measured at 24 hours post FPI. The reduction in this group of cytokines in the CD74Def mice, implicate CD74 in
their production following FPI. For these experiments we used five C57BL/6 and six CD74Def. The symbol * indicates P < 0.05.
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study supports the involvement of antigen processing
and presentation in the exacerbation of brain injury
[17,18,33,34]. While it is clear that CD74 is involved in
the damage to the CNS following TBI, several different
functions have also been attributed to CD74. These in-
clude: survival, signal transduction through cell surface
CD74, binding to pro-inflammatory macrophage inhibi-
tory factor (MIF), along with its well-established role in
antigen processing and presentation [35-38]. Based onFigure 6 CAP treatment after FPI reduces neurodegeneration and les
treated mice (A), significantly more degenerating neurons are observed co
(D) Analysis of the size of the lesion at 3 days after FPI revealed that CAP t
anterior/posterior plane, compared to sham mice. (E) Quantitative analysis
(P < .01 for both) labeled-cells in the CAP treated and CD74Def mice. For th
A-C = 50 μm. The symbol * indicates P < 0.01.the current findings, it is not possible to exclude any of
these functions of CD74 in mediating neurodegeneration
after TBI.
To further elucidate the putative role of CD74 in TBI,
we engineered a peptide that competitively antagonizes
the proteolytic product of CD74, CLIP [25]. We deter-
mined that administration of this potentially therapeutic
peptide 20 minutes after TBI prevented the increase in
splenic cellularity in all observed peripheral immune cell
populations with the exception of activated conventionalion size. (A-C) FluoroJade C labeling at 3 days after FPI. In vehicle
mpared to mice treated with CAP after FPI (B) and CD74def mice (C).
reatment and CD74Defmice had a significantly smaller lesion in the
of the number of FluorJade C-labeled cells showed significantly less
is analysis, we used 6 shams, 5 CAP and 5 CD74Defmice. Scale bars in
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peptide was neuroprotective following TBI, supporting
the notion that neuronal damage involves the transition
between innate and adaptive immunity.
The transition between innate and adaptive immun-
ity can be regulated by several subsets of activated,
non-conventional T cells, including Tregs and γδ T
cells. While Tregs have been well described to dampen
antigen-specific responses in the periphery, their role
in the CNS is controversial [39-41]. Moalem et al. has
proposed that following injury to the nervous system,
Tregs may be detrimental, because the antigen specific
T cell response that they limit may be protective [18,19,33].
Alternatively, some investigators have proposed protective
effects of Tregs following cerebral insults [40-43]. It is per-
tinent to note that two distinct subsets of Tregs have been
characterized, natural Tregs and inducible Tregs [44,45].
Therefore, it is possible that one population of Tregs is
beneficial and the other is detrimental. Future studies are
needed to examine this possibility.
The current results also demonstrated a significant ex-
pansion of γδ T cells after TBI that could be reversed with
CAP treatment. Freedman and colleagues previously dem-
onstrated the presence of γδ T cells in the cerebral spinal
fluid of patients with multiple sclerosis [46]. Additionally,
it has previously been shown that these γδ T cells could
attack oligodendrocytes, indicating the potential for a de-
structive response by γδ T cells in the CNS [46,47]. Our
data showing a reduced MHCII expression by γδ T cells
after FPI argues for reduced capability for antigen presen-
tation and processing. This reduced ability for antigen
presentation and processing could prevent an effective
transition from innate to adaptive immunity. Such preven-
tion of an effective transition to adaptive immunity could
undermine what would otherwise be protective auto-
immunity as previously suggested [18,33].
Similar to γδ T cells, B cells are also well described
as antigen specific, capable of producing antibodies, and
as exquisitely efficient professional antigen presenting
cells [21,22]. Our finding that after FPI, B cells have sig-
nificantly reduced CLIP, but not significantly reduced
MHCII, suggests that these cells have a higher likelihood
for antigen presentation after TBI [22]. In support of this
notion, a recent study showed that the antigen presenta-
tion function of B cells is critical for the pathology of ex-
perimental autoimmune encephalitis (EAE), more so than
auto-antibody production [34]. Thus, some consequences
of TBI might depend upon efficient antigen processing
and presentation by B cells.
The effector functions of B cells and T cells involve cyto-
kines and chemokines. These small molecule compounds
serve as chemotactic signaling proteins and immune mod-
ulators. Numerous studies have implicated a variety of
chemokines and cytokines in the pathogenesis of TBI [32].The interactions that govern the effects of cytokines are
poorly understood in general, and even less-well under-
stood in the context of TBI. In CD74Def mice, we observed
significantly less IFNγ and TNFα compared to WT con-
trols following FPI. Elevations of both of these cytokines
have been previously reported following various types of
TBI [48-52], but the cellular source(s) of these cytokines
and their functional significance are not well-defined.
While some studies demonstrate that glial cells, including
microglial cells are involved in the increase [53,54], the
possibility that infiltrating immune cells, including macro-
phages, contribute to these increases cannot be ruled out.
In support of this interpretation, we also observed de-
creased MIP1β (Figure 5) and RANTES, both of which are
products of CD8+ T cells [55,56], which were also reduced
with CAP (Figure 1). Nevertheless, our data with CD74Def
mice implicate antigen processing involving CD74 as a
contributor to the elevation of these cytokines and chemo-
kines after TBI.
While CCL2 is a well-described marker of inflammation
after TBI [57,58], and CAP reduced its expression in this
study, less understood is the putative roles of IL15, IL13
and IL10, that were also reduced by CAP. Interestingly, a
previous study using IL15 KO mice and IL15R KO mice
in a facial axotomy model, found reduced T cell infiltra-
tion and increased MHCII +microglial cells [59]. Consist-
ent with the potential involvement of macrophages/
microglial cells, IL13 has been previously shown to be in-
volved in the elimination of activated microglial cells sub-
sequent to an injury [60]. In our study, administration of
CAP reduced the lesion size, which could reflect a reduc-
tion in the number of activated microglial cells responding
to the injury, thereby decreasing the overall level of IL15
and IL-13. With regard to the CAP-dependent decrease in
IL-10, previous studies have indicated that elevated IL-10
corresponds with a poor outcome for patients [61,62].
Therefore, the reduction in IL-10 observed following CAP
treatment may be indicative of the decreased lesion size
and thus an improved outcome.
Conclusion
The synthesis of CAP was based on the rationale that an-
tagonism of CLIP would selectively target the transition
between innate and adaptive immunity. While our results
are consistent with this hypothesis, the consequences of
CAP therapy resulting in neuroprotection require further
examination to fully elucidate the precise mechanisms in-
volved. Nonetheless, the results from the current study
provide a foundation for targeting the switch between in-
nate and adaptive immunity for the treatment of TBI.
Moreover, our specific characterization of peripheral alter-
ations to distinct subsets of immune cells may provide
biomarkers for diagnosing and characterizing the degree
of TBI severity, progression and/or recovery.
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Additional file 1: Figure S1. Flow cytometric-gating strategy. Representative
5% contour plots of flow cytometric data to show gating strategy.
Additional file 2: Figure S2. The impact of CAP on the cell surface
levels of CLIP and MHCII on B and γδ T Cells. (A) The mean fluorescence
intensity (MFI) of CLIP on the surface of B cells in the spleens of C57BL/6
mice 24 hours following sham surgery or FPI. (B) The number of CLIP+ B
cells (B220+CLIP+). (C) The MFI of MHCII on the surface of B cells in the
spleens of C57BL/6 mice 24 hours following sham surgery or FPI. (D) The
MFI of CLIP on the surface of γδ T cells in the spleens of C57BL/6 mice
24 hours following sham surgery or FPI. (E) The MFI of MHCII on the
surface of γδ T cells in the spleens of C57BL/6 mice 24 hours following
sham surgery or FPI. Sham + CAP (N = 5); FPI + vehicle (N = 6).
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